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Background: The acid-suppressive agents have been linked with an increased risk of infectious disease. The relationship
between these drugs and Mycobacterium Tuberculosis (TB) was not been reported.
Methods: We conducted a case–control study using data from National Health Insurance research database of Taiwan.
From 1996 till 2008, and 6541 cases were defined as TB infection/activation (ICD-9 coding plus prescription two of four
first-line anti-TB regimen for at least one month). Control subjects who were matched to the TB cases by age and sex
were selected with 10:1 ratio. Medical records including acid-suppressive agent prescription and comorbidity, and
socioeconomic status were analyzed.
Results: TB infection/activation was more frequent to comorbidity with chronic diseases, alcohol abuse,
malignancy, immune deficient/suppression status and acid-related disease (peptic ulcer, reflux esophagitis).
Among the TB cases, there was higher exposure record to acid-suppressive agents within 3 months before TB
index date (OR 2.43(2.06-2.88) and 1.90 (1.68-2.14) for proton pump inhibitor (PPI) and histamine 2 receptor
antagonist (H2RA) respectively). After adjusting confounding factors, PPIs prescription 3 months before TB index
date had an association of TB infection/activation (adjusted OR 1.63(1.61-1.63)). Similar result was found in H2RA
user (adjusted OR 1.51(1.50-1.52)). The association of acid-suppressive agents in TB infection/activation was fade
gradually when the drug prescription period extended.
Conclusions: Recent prescription of acid-suppressive agent seems to associate the TB infection/activation. In
the society where TB was prevalent, evaluation of pulmonary TB before prescription of PPI or H2RA is warranted.
Keyword: Proton pump inhibitor, Histamine2-receptor antagonist, Mycobacterium Tuberculosis, National health
insurance database, TaiwanBackground
Gastric acid plays an important role in decontamination
of upper gastrointestinal tract. Following the widespread
use of acid-suppressive agents [1-3], which are the main-
stream of treatment in peptic ulcer disease and acid reflux
associated esophageal disease, its eliminating acid barrier
effect had been implied the association with infectious dis-
ease. Proton pump inhibitor (PPI) had marketed for more
than two decades, and several studies had mentioned its* Correspondence: kevinhu837@gmail.com
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reproduction in any medium, provided the ordirect link to several enteric infections, such as Clostridium
diffcile colitis, Salmonella enteritis [4,5] and spontaneous
bacterial peritonitis in patients with advanced cirrhosis [6].
In addition, some population- or hospital- based studies of
respiratory tract infection also revealed the increased risk of
nosocomial and community-acquired pneumonia in pa-
tients with PPI use, while the role of histamine 2 receptor
antagonist (H2RA) was controversial [7-9]. Among variant
respiratory tract infectious disease, Mycobacterium tubercu-
losis (TB) infection is still an important health problem in
many developing countries. With the characteristics of la-
tent and indolent phases and the emergence of drug resist-
ance [10], the resurgence of TB has great impact on public
health [11].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 ICD-9-CM codes used for Comorbidity
Congestive heart failure 428
Coronary heart disease 410-41405
Chronic pulmonary disease 493,494,501-5089
Diabetes Mellitus 2500-2509
End stage renal disease 585
Liver cirrhosis 5712,5715, 5716
Alcohol abuse 291,292,303,304, 305
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uncommon in developed countries, but it has re-emerged
in the Western countries as a result of the acquired
immunodeficiency syndrome (AIDS) epidemic therein
as well as the influx of immigrants from developing coun-
tries [12,13].
Previous reports have shown a high prevalence of tu-
berculosis among patients who have undergone gastrec-
tomy, and gastrectomy is considered to be a risk factor
for the development of tuberculosis. [14,15] But, the role
of gastric acid in TB infection was still unknown.
To our best knowledge, there was no large study which
examined the association between acid-suppressive agents
and TB. Here, we utilized the database from Taiwan Na-
tional Health Insurance (NHI) to evaluate its correlation
under a population-based, case–control analysis.
Methods
Study population and source of data
The NHI program was implemented in Taiwan since
1995, and it offered a comprehensive, unified, and uni-
versal health insurance program to all citizens. The
state-run Bureau of National Health Insurance (BNHI)
contracted with 97% of hospitals as well as 90% of
clinics. The BNHI collected all the administrative and
claim data between March 1995 and December 2009,
these data were anonymous.
The data was analyzed from the National Health Insur-
ance Research Dataset (NHIRD), published by the Na-
tional Health Research Institute (NHI) in Taiwan.
Taiwan’s National Health Insurance program insures ap-
proximately 23 million people, 99% of its population. It of-
fers complete freedom of choice among healthcare
providers contracted with the NHI and comprehensive
benefits including inpatient care, ambulatory care, dental
care, and prescription drugs. The NHI resources, includ-
ing physician visits, hospital care, and prescribed medica-
tions. Using this database, we can identify cohorts, track
medical history, establish a prescription drug profile, and
set endpoints when researching outcomes. Therefore, the
NHIRD is one of the largest and most complete nation-
wide population-based datasets in Taiwan and there were
no statistically significant differences in age, sex, and aver-
age insured payroll-related amount between the sample
group and all enrollees.
This study used the 1996–2008 National Health Insur-
ance Research Database (NHIRD) that is derived from
NHI program which provided a database of 1,000,000 ran-
dom subjects for research purposes.
Because these were secondary data, each patient’s ori-
ginal identification number has been encrypted to protect
privacy by a consistent procedure, so that the linkage of
claims belonging to the same patient is feasible within the
NHI Research Database.Definition of TB infection/activation
We defined active TB from NHRID by compatible ICD-
9-CM (International Classification of Disease, 9th Revi-
sion, Clinical Modification) codes of TB (010–108) plus
the prescription of two of four first-line anti-tuberculosis
medications (rifampin, isoniazid, pyrazinamide, etham-
butol) for more than 28 days.
All patients who had match TB inclusion criteria were in-
cluded. Under this definition, both of new symptomatic in-
fection and reactivation who need treatment were included.
Theoretically, It also included pulmonary, extra-pulmonary,
child and adult. Ultimately, 6,541 patients with TB were in-
cluded in the study group. Their first ambulatory care visits
was assigned as index ambulatory care visits.Control group
Matched controls group for this study was likewise ex-
tracted from the Registry of Beneficiaries of the NHIRD.
We randomly selected 65,410 control subjects (10 for
every TB patient), matched with the study group in terms
of age, sex and the year and month of index visit.Comorbidity
Several underline diseases had been shown to increase
the risk of TB infection/activation [16,17], we collected
those ICD-9 coding as confounding variables. Further-
more, gastric acid-related gastrointestinal diseases which
act as a predictor of using acid-suppressive medication
were also included for comorbidity analysis (Table 1).
The definition of cormobidity was defined when those
ICD-9 coding existed within 3 months before the diag-
nostic date of TB infection/activation.
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Acid-suppressive agents included PPI (omeprazole, panto-
prazole, lanosoprazole, rabeprazole, esomeprazole) and
H2RA (cimetidine, ranitidine, famotidine) which were mar-
keted in Taiwan during the observing period. The exposure
of acid- suppressive agents was considered when the aver-
age dosage was more than half of the defined daily dose
(DDD) during the observing period. The defined daily dose
(DDD) recommended by the WHO is a unit for measuring
a prescribed amount of drug; it is the assumed average
maintenance dose per day of a drug consumed for its main
indication in adults. We estimated dose–response relation-
ship by using the cumulative amount of PPIs redeemed
during the past 90 days, past 180 days, past 1 year and past
2 year as four periods. Cut-off points were greater than
50% DDD and non-use.
Statistical analysis
Chi-square test was used to compare the distribution of
sociodemographic characteristics between patients with
and patients without TB. We characterized comorbidity
(Table 1) 1 year before index date. The crude and adjusted
ORs with 95% confidence intervals (CIs) of exposure for
TB cases compared with control subjects were estimated
using logistical regression. Previous diagnosis of comorbid-
ity were either risk factors in univariate analyses of tuber-
culosis or were found to modify the OR for the association
between acid suppressive agent and TB by at least 5% if in-
cluded in a multivariate model. All these priori confound-
ing factor were included in the multivariate analysis.
Multivariate analysis was utilized to adjust variable con-
founding factors in order to identify the association be-
tween acid-suppressive agents and TB infection/activation.
All the data processing and statistical analysis were per-
formed with SAS 9.3 software.
Results
Between 1996 and 2008, there were 6541 patients who
met the criteria of TB infection/activation. The character-
istics of TB cases and controls were presented in Table 2.
A p value < 0.05 was considered statistically significant.
Similar with previous studies, TB infection/activation was
more frequent to comorbid with chronic diseases, alcohol
abuse, malignancy and immune deficient/suppression sta-
tus. Interestingly, TB cases also had higher prevalence of
both peptic ulcer disease (16.90% vs. 10.43% of controls,
OR 1.75, 95% CI 1.63-1.87) and reflux esophagitis (1.57%
vs. 1.02% of controls, OR 1.56, 95% CI 1.27-1.92) within
three months before the TB diagnosis. As for the use of
acid-suppressive agents, 173 out of 6541 TB cases (2.64%)
and 723 out of 65410 controls (1.11%) were exposed to
PPI medication within 3 months of diagnosis. During the
same period, the use of H2RA in TB cases and controls
were 5.16% and 2.79%, respectively. After adjusting theconfounding variables, their adjusted odds ratio (aOR) of
using PPI or H2RA in TB cases were1.63 (95% CI 1.61-
1.63) (Table 3) and 1.51 (95% CI, 1.50-1.52) (Table 4),
respectively.
In order to clarify the association of long-term use of
acid-suppressive agents and TB infection/activation, we
also observed the prevalence of PPI or H2RA use by defin-
ition of DDD higher than 50% within 6, 12 and 24 months
before TB diagnosis (Tables 3 and 4). The higher possibil-
ity of PPI use in TB cases was still noted in 6 months in
comparison to controls (aOR, 1.29, 95%CI 1.29-1.30).
However, the positive association disappeared in 12 and
24 months observing timeframe (Table 3). Similarly, the
decreasing trend of association between H2RA and TB fol-
lowing the extension of observing timeframe was also
found (Table 4). As the result, the influence of acid-
suppressive agents in TB infection/activation was fade
gradually when the drug prescription period extended
(Figure 1).
Discussion
Acidic environment of stomach usually keep free from
bacteria (except for Helicobacter pylori). Somehow, when
stomach becomes less acidic, it loses this protective
mechanism, and ingested organisms can survive and
proliferate.[18]. It also can be the possible reason for the
acid-suppressive agent with pneumonia. In Laheij et al.
study, which 5,551 cases of community-acquired pneu-
monia developed in 364,683 people, found that the inci-
dence of pneumonia was about 4.5 times higher in
people exposed to acid-suppressive drugs (both PPIs and
H2RA) than in unexposed individuals.[7]. Subsequent
had the similar results discussing the association of PPI
with community-acquired pneumonia. [9,19-23]. Patients
who developed community acquired pneumonia had
higher odds of significant comorbidity conditions, includ-
ing heart failure and chronic obstructive pulmonary dis-
ease. This possible association came to the attention of the
general medical community. Although, the risk factors of
pneumonia were complicated, the most important risk
factor of pneumonia were aging, immunocompromised
status and comorbility, [24,25] which may overcome the
importance of acid-suppressive agent.
Mycobacterium tuberculosis infection can present as an
acute process and should be included in the differential
diagnosis of community-acquired pneumonia. It is in-
fected by Mycobacterium tuberculosis and may mimic
classic bacterial pneumonia or masquerade as an atypical
pneumonia, with nonproductive cough. Epidemiologic
clues Mycobacterium tuberculosis share similar risk factor
with community acquired pneumonia such as Diabetes
mellitus, alcohol consumption, aging and HIV infection.
In addition, intravenous drug abuse, immigration from
countries of high prevalence, contact with Mycobacterium
Table 3 Association between variable duration of PPI exposure and TB infection/activation
Exposure Case (%) n = 6541 Control (%) n = 65410 Crude OR Adjusted OR†
3 months
Non user 6368(97.36) 64687(98.89) 1 1
User 173(2.64) 723(1.11) 2.43(2.06-2.88) 1.63(1.62-1.63)
6 months
Non user 6306(96.41) 64276(98.27) 1 1
User 235(3.59) 1134(1.73) 2.11(1.83-2.44) 1.29(1.29-1.30)
12 months
Non user 6221(95.11) 63575(97.19) 1 1
User 320(4.89) 1835(2.81) 1.78(1.58-2.01) 0.99(0.99-1.01)
24 months
Non user 6103(93.30) 62519(95.58) 1 1
User 438(6.70) 2891(4.42) 1.55(1.40-1.72) 0.90(0.89-0.90)
Abbreviations: OR, odds ratio. †Adjusted for socioeconomic status, congestive heart failure, coronary heart disease, chronic pulmonary disease, diabetes mellitus,
end stage renal disease, liver cirrhosis, alcohol abuse, peptic ulcer disease, reflux esophagitis, gastrectomy, HIV, connective tissue disease, malignant neoplasm,
organ transplantation.
Table 2 Characteristics of cases with TB infection/activation and control subjects
Characteristics Case n = 6541 (%) Control n = 65410 (%) OR (95%CI)
Age (mean ± SD) 57.78(±19.55)
Sex Male/Female 4277/2264 42770/22640 1.0000
Income category
Monthly income ≦ NT$20000 5371(82.11) 52016(79.52) 0.79-0.90
Monthly income > NT$20000 1170(17.89) 13394(20.48)
Comorbidity
Congestive heart failure 304(4.65) 1224(1.87) 2.56(2.25-2.91)
Coronary heart disease 727(11.11) 5674(8.67) 1.32(1.21-1.43)
Chronic pulmonary disease 1087(16.62) 2524(3.86) 4.97(4.60-5.36)
Diabetes mellitus 1274(19.48) 6234(9.53) 2.30(2.14-2.45)
End stage renal disease 182(2.82) 799(1.22) 2.32(1.97-2.73)
Liver cirrhosis 696(10.64) 3952(6.04) 1.85(1.70-2.02)
Alcohol abuse 91(1.39) 229(0.35) 4.02(2.15-5.13)
Peptic ulcer disease 1106(16.90) 6823(10.43) 1.75(1.63-1.87)
Reflux esophagitis 103(1.57) 664(1.02) 1.56(1.27-1.92)
Gastrectomy 23(0.35) 149(0.23) 1.55(1.01-2.40)
HIV 12 (0.18) 3(0.00) 40.04(11.3-141.9)
Connective tissue disease 245(3.75) 1357(2.07) 1.84(1.60-2.11)
Malignant neoplasm 704(10.76) 1906(2.91) 4.02(3.67-4.40)
Organ transplantation 21(0.32) 58(0.08) 3.63(2.20-5.99)
Medication
PPI 173(2.64) 723(1.11) 2.43(2.06-2.88)
H2RA 338(5.16) 1828(2.79) 1.90(1.68-2.14)
Abbreviations: TB, Mycobacterium Tuberculosis; CI, confidence interval; SD, standard deviation; NT, New Taiwan dollars; OR, odds ratio; HIV, human immunodeficiency
virus; PPI, proton pump inhibitor; H2RA, histamine2-receptor antagonist.
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Table 4 Association between variable duration of H2RA exposure and TB infection/activation
Exposure Case (%) n=6541 Control (%) n=65410 Crude OR Adjusted OR†
3 months
Non user 6203(94.83) 63582(97.21) 1 1
User 338(5.17) 1828(2.79) 1.90(1.68-2.14) 1.51(1.50-1.52)
6 months
Non user 6073(92.85) 62528(95.59) 1 1
User 468(7.15) 2882(4.41) 1.67(1.51-1.85) 1.29(1.28-1.29)
12 months
Non user 5847(89.39) 60678(92.77) 1 1
User 694(10.61) 4732(7.23) 1.52(1.40-1.66) 1.15(1.14-1.15)
24 months
Non user 5549(84.83) 57998(88.67) 1 1
User 992(15.17) 7412(11.33) 1.40(1.30-1.50) 1.06(1.05-1.06)
Abbreviations: OR, odds ratio. †Adjusted for socioeconomic status, congestive heart failure, coronary heart disease, chronic pulmonary disease, diabetes mellitus,
end stage renal disease, liver cirrhosis, alcohol abuse, peptic ulcer disease, reflux esophagitis, gastrectomy, HIV, connective tissue disease, malignant neoplasm,
organ transplantation.
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[11,26,27]. Gastrectomy had also considered an isolated
risk factor of Mycobacterium tuberculosis.[14,28] Gastrec-
tomy can cause a poor nutritional status leading to poor
immunity, and also leads to a poor nutritional status.
[29,30]. Long-term PPI therapy has been thought to be
associated with micronutrient deficiencies, especially of
iron and vitamin B12.[31]. However, the relation be-
tween acid suppressive agent and Mycobacterium tuber-
culosis infection was still unknown.
In the present study, the risk of TB infection/activation
increased when comorbidity existed, compatible with previ-
ous findings. After adjusting these confounding factors,
acid-suppressive agents associated with an increasing of TBFigure 1 Association between the using of proton pump
inhibitors (PPIs), histamine2-receptor antagonist (H2RA) and
Mycobacterium tuberculosis infection/activation, according to
the timing of acid suppressed agents prescription.
AORs indicate odds ratios.infection/activation. However, the longer duration the med-
ications were prescribed, the weaker correlation it showed.
Two hypothesis was considered to the statistical associ-
ation of TB and acid-suppressive agent. One was the acid-
suppressive agent had influence to the host immune or
nutrition status and cause the host sensitive to TB infec-
tion/reactivation. It effect declined with time. The other
was initial TB presentation (chronic cough) mimicking
acid-related disease and caused the prescription of acid-
suppressive agent.
Here we defined acid-suppressive agent exposure as the
average dosage during the observing period higher than
50% of DDD. The duration of acid-suppressive agent pre-
scription suggested by NHI guideline was within 4 months
after endoscopic diagnosis of peptic ulcers or reflux
esophagitis. It seem that acid-suppressive agents were pre-
scribed before TB infection/activation was diagnosed in 3
and 6 months subgroups. Interestingly, in comorbidity
analysis, reflux esophagitis was also a risk factor of TB in-
fection/activation. In clinical practice, the acid reflux
might be on the list of differential diagnosis for cases who
suffered from chronic cough, giving another chance that
acid-suppressive agents were taken before anti-TB drug
prescription.
The main strength of the present study lies in the use of
a true population-based approach, with comprehensive
medical records for personal health issue. However, there
were some limitations. First, the TB prevalence in the
present study was about 49.3 per 100,000 population per
year, which was lower than the crude incidence (74.6 per
100,000 population) in Taiwan. [11,32] The reason of
underestimated prevalence might come from the defin-
ition of TB infection/activation we used, which combined
coding system and anti-TB drug prescription record.
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ment were eliminated from study group. On the contrary,
utilizing prescription record could minimize the bias of
miscoding. Second, the present study focused on the med-
ical record from NHI research database, which did not
include the acid-suppressive agents prescribed from over-
the-counter medication. It might underestimate the effect
of PPI and H2RA. Furthermore, it was also difficult to
evaluate the drug compliance. Third, some risk factors as-
sociated with immunocompromised status, such as poorly
controlled diabetes, underweight, malnutrition, were not
available, and these factors were possibly influence the TB
activation. Fourth, we separated arbitrarily the using of
acid suppressive agent in the interval of 3,6,12,24 months
and define the exposure as DDD exceeded 50%. This def-
inition would blur the different influence of long-term,
short-term, on-off prescription and on-demand prescrip-
tion. Further prospective study would warrant to this
issue.
Undoubtedly, acid-suppressive agents are of great value
for treatment of peptic ulcer disease, gastroesophageal re-
flux disease, or for prophylaxis against nonsteroid anti-
inflammatory drug–related gastrointestinal complications.
Following the increase in PPI use in Taiwan [33], the ad-
verse effect of the drug needs to be further noticed. Similar
as the possible role in community-acquired pneumonia, re-
cent prescription of acid-suppressive agent seems to associ-
ate the TB infection/activation. Under the consideration of
initial TB infection/activation mimic atypical reflux esopha-
gitis, in the society where Mycobacterium tuberculosis was
prevalent, evaluation of pulmonary TB was warranted be-
fore prescription of acid-suppressive agent.
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